The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy treatments.
#Icad investor relations skin
The Xoft System is FDA-cleared and CE marked for use anywhere in the body, including treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers.
iCAD's Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is a painless, non-invasive technology that delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast and colorectal cancers. ICAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while improving patient outcomes. Location: Luxe Sunset Bel Air Hotel, Los Angeles, CA Location: The Depot Renaissance Minneapolis Hotel, Minneapolis, MNħ th Annual LD Micro Invitational Conference Details NASHUA, N.H., (GLOBE NEWSWIRE) - iCAD, Inc.(Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that management will be participating in the 14 th Annual Craig-Hallum Institutional Investor Conference, as well as presenting at the 7 th Annual LD Micro Invitational Conference.ġ4 th Annual Craig-Hallum Institutional Investor Conference Detailsįormat: One-on-One meetings.